The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
12 2020
Historique:
received: 08 07 2020
revised: 30 09 2020
accepted: 09 10 2020
pubmed: 23 10 2020
medline: 15 12 2020
entrez: 22 10 2020
Statut: ppublish

Résumé

The risk of pulmonary embolism (PE) in patients with Coronavirus Disease 2019 (COVID-19) is recognized. The prevalence of PE in patients with respiratory deterioration at the Emergency Department (ED), the regular ward, and the Intensive Care Unit (ICU) are not well-established. We aimed to investigate how often PE was present in individuals with COVID-19 and respiratory deterioration in different settings, and whether or not disease severity as measured by CT-severity score (CTSS) was related to the occurrence of PE. Between April 6th and May 3rd, we enrolled 60 consecutive adult patients with confirmed COVID-19 from the ED, regular ward and ICU who met the pre-specified criteria for respiratory deterioration. A total of 24 (24/60: 40% (95% CI: 28-54%)) patients were diagnosed with PE, of whom 6 were in the ED (6/23: 26% (95% CI: 10-46%)), 8 in the regular ward (8/24: 33% (95% CI: 16-55%)), and 10 in the ICU (10/13: 77% (95% CI: 46-95%)). CTSS (per unit) was not associated with the occurrence of PE (age and sex-adjusted OR 1.06 (95%CI 0.98-1.15)). The number of PE diagnosis among patients with COVID-19 and respiratory deterioration was high; 26% in the ED, 33% in the regular ward and 77% in the ICU respectively. In our cohort CTSS was not associated with the occurrence of PE. Based on the high number of patients diagnosed with PE among those scanned we recommend a low threshold for performing computed tomography angiography in patients with COVID-19 and respiratory deterioration.

Sections du résumé

BACKGROUND
The risk of pulmonary embolism (PE) in patients with Coronavirus Disease 2019 (COVID-19) is recognized. The prevalence of PE in patients with respiratory deterioration at the Emergency Department (ED), the regular ward, and the Intensive Care Unit (ICU) are not well-established.
OBJECTIVES
We aimed to investigate how often PE was present in individuals with COVID-19 and respiratory deterioration in different settings, and whether or not disease severity as measured by CT-severity score (CTSS) was related to the occurrence of PE.
PATIENTS/METHODS
Between April 6th and May 3rd, we enrolled 60 consecutive adult patients with confirmed COVID-19 from the ED, regular ward and ICU who met the pre-specified criteria for respiratory deterioration.
RESULTS
A total of 24 (24/60: 40% (95% CI: 28-54%)) patients were diagnosed with PE, of whom 6 were in the ED (6/23: 26% (95% CI: 10-46%)), 8 in the regular ward (8/24: 33% (95% CI: 16-55%)), and 10 in the ICU (10/13: 77% (95% CI: 46-95%)). CTSS (per unit) was not associated with the occurrence of PE (age and sex-adjusted OR 1.06 (95%CI 0.98-1.15)).
CONCLUSION
The number of PE diagnosis among patients with COVID-19 and respiratory deterioration was high; 26% in the ED, 33% in the regular ward and 77% in the ICU respectively. In our cohort CTSS was not associated with the occurrence of PE. Based on the high number of patients diagnosed with PE among those scanned we recommend a low threshold for performing computed tomography angiography in patients with COVID-19 and respiratory deterioration.

Identifiants

pubmed: 33091701
pii: S0049-3848(20)30556-9
doi: 10.1016/j.thromres.2020.10.012
pmc: PMC7557291
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

486-490

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Thromb Res. 2020 Aug;192:23-26
pubmed: 32405101
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
Ann Emerg Med. 2004 Nov;44(5):503-10
pubmed: 15520710
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
BMJ Open. 2019 Oct 10;9(10):e031639
pubmed: 31601598
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
TH Open. 2020 Jun 08;4(2):e113-e115
pubmed: 32529170
Thromb Res. 2020 Sep;193:1-4
pubmed: 32485437
Thromb Res. 2020 Sep;193:86-89
pubmed: 32531548
Radiology. 2020 Sep;296(3):E186-E188
pubmed: 32324103
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32398297
Thromb Haemost. 2020 Aug;120(8):1230-1232
pubmed: 32349132
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
BMJ Open. 2020 Sep 29;10(9):e040175
pubmed: 32994259

Auteurs

Renée A G Brüggemann (RAG)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. Electronic address: renee.bruggemann@mumc.nl.

Bart Spaetgens (B)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Hester A Gietema (HA)

Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands; Grow school of Oncology and Developmental biology, Maastricht, the Netherlands.

Steffie H A Brouns (SHA)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Patricia M Stassen (PM)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Fabienne J Magdelijns (FJ)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Roger J Rennenberg (RJ)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Ronald M A Henry (RMA)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Mark M G Mulder (MMG)

Department of Intensive Care, Maastricht University Medical Centre+, Maastricht, the Netherlands.

Bas C T van Bussel (BCT)

Department of Intensive Care, Maastricht University Medical Centre+, Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.

Ronny M Schnabel (RM)

Department of Intensive Care, Maastricht University Medical Centre+, Maastricht, the Netherlands.

Iwan C C van der Horst (ICC)

Department of Intensive Care, Maastricht University Medical Centre+, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+, Maastricht, the Netherlands.

Joachim E Wildberger (JE)

Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+, Maastricht, the Netherlands.

Coen D A Stehouwer (CDA)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+, Maastricht, the Netherlands.

Hugo Ten Cate (H)

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+, Maastricht, the Netherlands; Thrombosis Expert Centre Maastricht and Department of Internal Medicine, Section Vascular Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH